GCK and hyperlipidemia: Glucokinase activator SHP289-04 significantly improves hyperglycemia and hyperlipidemia in KKAy mice [16] and glucokinase mediates the expression of insulin receptor substrate 2 to alleviate islet β-cell apoptosis caused by endoplasmic reticulum stress [17].